Drew Janice Suzann 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Drew Janice Suzann
EVP, Operations
Transactions
- Conversion
Common Stock
2025-11-07+1,587→ 72,868 total - Conversion
Series B Preferred Stock
2025-11-07−12,500→ 0 total→ Common Stock (1,587 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.